Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
DLC1-dependent parathyroid hormone–like hormone inhibition suppresses breast cancer bone metastasis
Yufeng Wang, … , Qifeng Yang, Guohong Hu
Yufeng Wang, … , Qifeng Yang, Guohong Hu
Published March 3, 2014
Citation Information: J Clin Invest. 2014;124(4):1646-1659. https://doi.org/10.1172/JCI71812.
View: Text | PDF
Research Article Oncology

DLC1-dependent parathyroid hormone–like hormone inhibition suppresses breast cancer bone metastasis

  • Text
  • PDF
Abstract

Bone metastasis is a frequent complication of breast cancer that is often accelerated by TGF-β signaling; however, little is known about how the TGF-β pathway is regulated during bone metastasis. Here we report that deleted in liver cancer 1 (DLC1) is an important regulator of TGF-β responses and osteolytic metastasis of breast cancer cells. In murine models, breast cancer cells lacking DLC1 expression exhibited enhanced capabilities of bone metastasis. Knockdown of DLC1 in cancer cells promoted bone metastasis, leading to manifested osteolysis and accelerated death in mice, while DLC1 overexpression suppressed bone metastasis. Activation of Rho-ROCK signaling in the absence of DLC1 mediated SMAD3 linker region phosphorylation and TGF-β–induced expression of parathyroid hormone–like hormone (PTHLH), leading to osteoclast maturation for osteolytic colonization. Furthermore, pharmacological inhibition of Rho-ROCK effectively reduced PTHLH production and breast cancer bone metastasis in vitro and in vivo. Evaluation of clinical breast tumor samples revealed that reduced DLC1 expression was linked to elevated PTHLH expression and organ-specific metastasis to bone. Overall, our findings define a stroma-dependent paradigm of Rho signaling in cancer and implicate Rho–TGF-β crosstalk in osteolytic bone metastasis.

Authors

Yufeng Wang, Rong Lei, Xueqian Zhuang, Ning Zhang, Hong Pan, Gang Li, Jing Hu, Xiaoqi Pan, Qian Tao, Da Fu, Jianru Xiao, Y. Eugene Chin, Yibin Kang, Qifeng Yang, Guohong Hu

×

Figure 2

The GTPase pathway mediates DLC1’s role in breast cancer metastasis.

Options: View larger image (or click on image) Download as PowerPoint
The GTPase pathway mediates DLC1’s role in breast cancer metastasis.
(A)...
(A) Activation of Rho, CDC42, and their downstream effectors in cells with DLC1 KD and OE. (B) Effect of DLC1 on stress fiber formation. (C) Stress fiber density (n = 6). (D) WT DLC1 and R718E mutant OE in SCP2 cells. (E) The R718E mutant failed to inactivate Rho and CDC42. (F–H) In vivo bone metastasis analysis of the R718E mutant (n = 10 per group). Shown are representative BLI images and H&E staining (F), BLI quantitation (G), and animal survival (H). Scale bars: 10 μm (B); 50 μm (F). *P < 0.05, **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts